SCHEMBL6476004

SCHEMBL6476004

CCNc1ccc(CCCc2ccc(Nc3ccccc3C(=O)OC)cc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.59
ALOX15 P16050 1/20 0.59
SIRT2 Q8IXJ6 2/20 0.50
KDM4E B2RXH2 3/20 0.48
GAA P10253 1/20 0.48
GLA P06280 1/20 0.47
ALDH1A1 P00352 2/20 0.47
KMT2A Q03164 2/20 0.46
POLB P06746 2/20 0.46
ATM Q13315 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
MEN1 O00255 1/20 0.44
RECQL P46063 1/20 0.44
BLM P54132 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C19 P33261 1/20 0.44
HTT P42858 1/20 0.43
ABCG2 Q9UNQ0 2/20 0.43
AURKA O14965 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6483326 0.87 MEN1 (0.58) MAPTALOX15SIRT2ALDH1A1KMT2A
SCHEMBL6485882 0.86 MAPT (0.61) MAPTALOX15SIRT2KDM4EGAA
SCHEMBL6474231 0.84 MAPT (0.56) MAPTALOX15SIRT2KDM4EGAA
SCHEMBL6474311 0.82 KMT2A (0.69) MAPTALOX15SIRT2KDM4EGAA
SCHEMBL13224505 0.81 MAPT (0.89) MAPTALOX15SIRT2KDM4EGAA
SCHEMBL6482028 0.78 PLK1 (0.57) MAPTSIRT2ALDH1A1KMT2APOLB
SCHEMBL12109319 0.76 MAPT (0.81) MAPTALOX15SIRT2KDM4EGAA
SCHEMBL1903514 0.76 KDM4E (0.70) MAPTALOX15KDM4EGAAGLA
SCHEMBL31914 0.76 MAPT (1.00) MAPTALOX15SIRT2KDM4EGAA
SCHEMBL6474762 0.76 MAPT (0.57) MAPTALOX15SIRT2KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US disclosed
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-11-04 US disclosed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP disclosed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits APP, PSEN1, BACE1 MAPT 6/4885ALOX15 2982/4885SIRT2 2735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.